Product Releases
DNA Reference Standard for Tumor Profiling
Thu, 2024-03-07 12:06
LISTED UNDER:
Horizon Diagnostics, a division of Horizon Discovery, announced it has launched its first Quantitative Multiplex DNA Reference Standard. This standard is the first of its kind and is intended for researchers assessing multiple biomarkers in a single assay, using platforms such as next generation sequencing (NGS). As multiplex assays and large tumor profiling projects become more common, standardization will be essential to enable confidence in experimental results. To date, a significant challenge has been access to reliable, renewable external reference standards. The reference standard directly addresses this need by enabling researchers to quantify a range of detection thresholds for 11 cancer relevant mutations. This is accomplished across complex samples in a single assay in the form of renewable material originating from precisely engineered cell lines. The reference standard is available as genomic DNA and will be available in a matched formalin fixed paraffin embedded (FFPE) format in Q2, 2013. The mutations were engineered into endogenous loci using Horizon’s proprietary genome editing platform, GENESIS. The reference standard was verified using digital PCR and the product has undergone extensive validation by external partners using NGS platforms such as Ion Torrent. Further validation is planned using MiSeq and Sequenom Mass Array Platforms.
Horizon Diagnostics, 800-860-3546, www.horizondx.com
